Nora Chokr

Bone Marrow Transplant MD| Cellular Therapy | Hematology & Oncology @AUBMC_official alum

[Institute for Experimental Cell Therapy, UK-Essen @IztfE]

We are very pleased that the new EBMT Guidelines on HLA in HCT produced within the Practice Harmonisation & Guidelines Workshop that we coordinated together with @AnnalisaRugger1 and @TheEBMT_CTIWP are now out in @BMTjournal .
Thanks to all contributors!

https://t.co/BfvLoKzZGb

[Joshua Zeidner MD @LeukDocJZ]

PASHA Trial- RP3 study of 7+3+Gilt or Mido for ND FLT3m AML. No difference in OS or CR but significant EFS & RFS improvement with Gilt given lots of crossover on Mido arm receiving Gilt salvage. Interesting results but hard to see where Gilt would fit in induction. #EHA26

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This review paper provides an updated overview of the current strategies and recommendations for fertility preservations that should be offered to all children and adolescents undergoing an #alloHSCT. Read: https://t.co/cAQw7Rxqkt

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

A must read for all hematopathologists and heme molecular pathologists congratulations to @DrChrisHourigan and team on this very important publication
@BloodPortfolio

https://t.co/Slbi8to8um

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

A moment of pride! A co-first author in the best journal in medicine for a clinical trial that resulted in FDA approval in the USA and is changing how we treat acute myeloid leukemia #AMLsm. Congratulations to all the authors لحظة فخر! باحث أول مشارك في أفضل مجلة علمية في الطب لتجربة إكلينيكية أدت إلى موافقة إدارة الغذاء والدواء الأمريكية وتغير الطريقة التي نعالج بها اللوكيميا النخاعية الحادة.

[WCMHemOncFellow @WCMHemOncFellow]

We’re so proud of our 4 fellows who received Young Investigator Awards at #ASCO26!

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

I look forward to this very important presentation in #EHA2026 about value of transplant in TP53 mutated #MDSsm and #AMLsm. The results clearly indicate a tail at end of curve and around 20% 23-year OS even among biallelic TP53mut patients, and especially in those with lower blast counts. Do NOT deprive patients from the opportunity of transplant without a very well-informed discussion!

Patients with KPS >80 had an estimated 3-year OS of 49.3%, compared with 30.2% for KPS ≤80. Biallelic TP53 was associated with inferior survival (HR 4.05, 95% CI 1.76–9.32; p=0.001) (figure 1b), reaching statistical significance only in the MDS subgroup. A low blast count at diagnosis was associated with improved survival (HR 0.50, 95% CI 0.29–0.88; p=0.02).

No clear associations were observed for age, HCT-CI, donor type, conditioning intensity or ATG. NRM did not differ significantly between MDS and AML (figure 1c).

ALLOGENEIC HSCT FOR TP53-ABERRANT MYELOID NEOPLASMS: REAL-WORLD... - Myhre A - EHA-6995 - Jun 13 2026

[Shernan Holtan MD @sghmd]

How complex is care delivery in a transplant and cellular therapy program? 🤔

We often talk about this in abstract terms, but when you map it out, the reality is striking. Allo HCT/BMT is one of the most medically complex procedures that can be performed, but it also currently has *excellent* outcomes, so programs shouldn't shy away from implementation. It just takes expertise, great acute care facilities, and thoughtful long-term follow up (much of which can now be done via telemedicine).

I created this figure using solid organ transplantation as a reference point to illustrate the layers of coordination, decision-making, and longitudinal management required.

From donor selection to acute peri-procedural care to lifelong follow-up, the system is far more intricate than many appreciate.

Curious how this resonates with others in the field. Does this reflect your experience? What key elements would you add or refine?

[Blood Journals Portfolio @BloodPortfolio]

The identified immune marker panel enables the development of an individualized approach to preventing and treating aGVHD in pediatric HCT. Read the full article in Blood ICT: https://t.co/kPhIgSH7wq

[Haematologica @Haematologica]

PROS AND CONS EDITORIAL
In the era of tyrosine kinase inhibitors, should all patients with FLT3-ITD acute myeloid leukemia still undergo allogeneic transplantation in first complete remission? A PRO perspective revisits this key clinical question.
https://t.co/C8XEHcp2yX

[Joshua Zeidner MD @LeukDocJZ]

Huge congratulations to Amir Fathi for delivering one of the most impactful plenary presentations @ASH_hematology in AML in past decade. The PARADIGM study may lead to a Paradigm shift- Aza/Ven > intensive chemo in newly Dx high-risk AML. 👏👏👏

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

The new 2025 @ASH_hematology Guidelines for Treating Newly Diagnosed #AMLsm in Older Adults are now online! 🩸🎗️🩸 We provide 9 critical clinical recommendations mirroring real-time practitioner-patient conversations. @SylvesterCancer @BloodAdvances https://t.co/E9JUa2mML3

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This new review article offers expert recommendations on a tiered approach to physical function assessment in transplant and #CART recipients to support patient care, reduce toxicity and improve data consistency across centers. Read: https://t.co/Z53vLMixvV

[Blood Journals Portfolio @BloodPortfolio]

Persistence of IDH1 mutations in complete remission is not associated with increased risk of relapse in AML. Mutant IDH2 MRD in complete remission is associated with higher relapse risk in mutant IDH2 AML without concomitant mutant NPM1 or FLT3-ITD. Read: https://t.co/XEFmmtsHC1

[Shernan Holtan MD @sghmd]

Conflict of research interest: I prescribe #sirolimus and also feel myself rapidly #aging 😂 🤔, so naturally I've always wondered if sirolimus helped slow the clock when used in allogeneic HCT. Hats off to Drs. Najla El Jurdi @NIH and @MattYousefzadeh @Columbia for digging into this question! In this unique pilot analysis, standard sirolimus dosing didn’t meaningfully lower senescence markers compared with cyclosporine. Maybe the #senotherapeutic window is narrower than how we use it in #BMT, and we still need to look for better ways to address age acceleration after #cancer therapy.

https://t.co/Bt3KaBUNv0

[Christine A. Garcia, MD, MPH @christinemphmd]

Congrats Drs. Evelyn Orlando & Herman van Besien for participating in the @lymphoma Lymphoma Scientific Research Mentoring Program (LSRMP). Great opportunity for @HemOncFellows to workshop their research protocols w/ lymphoma experts! @WCMHemOncFellow @ev_lando @HBesien

[Weill Cornell BMT Program @WeillCornellBMT]

Drs. Alexandra Gomez (@AGomez_MD) and Nora Chokr (@NChokr)’s article on the impact of disparities in access to #StemCellTransplant and strategies to promote representation in #PrecisionMedicine was featured in the current special issue of @nature #BMT: https://t.co/xsLlpm33V9

[Weill Cornell BMT Program @WeillCornellBMT]

Applications for the 2026 @WeillCornell @nyphospital advanced Bone Marrow Transplant (#BMT) and #CellularTherapy fellowship are open. Apply for the opportunity to join our team in July 2026: https://t.co/conoTLQKoZ

[Christine A. Garcia, MD, MPH @christinemphmd]

Thanks @nyphospital for a fun night on Broadway for @leftontenthplay. Wonderful to see our @WCMLeukemia team highlighted esp Drs. Gail Roboz & Koen Van Besien. Thanks @DeliaEphron for sharing your story!
@WCMHemOncFellow
@joshuafein
@ev_lando @MollyGilligan1 @LeukemiaAwarene

[Razan Mohty @Razan_Mohty]

Dr @Mohty_EBMT elegantly discussing the complex question of donor choice.

👇check the summary slide

#ASH24 #ASH24rm @ASH_hematology